This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Santis, S. Articles by Aloe, L. Search for Related Content PubMed PubMed Citation Articles by De Santis, S. Articles by Aloe, L.

Patients Treated with Antitumor Drugs Displaying Neurological Deficits Are Characterized by a Low Circulating Level of Nerve Growth Factor¹

Division of Medical Oncology, San Carlo Hospital, 85100 Potenza, Italy [S. D. S., L. M.]; Division of Medical Oncology and Service of Neurology, Istituto Regina Elena, 00161 Rome, Italy [A. P., A. S., L. B., B. J., F. C.]; and Institute of Neurobiology, Consiglio Nazionale delle Ricerche, 00137 Rome, Italy [F. P., M. F., V. T., M. D. S., L. A.]

The aim of our study was to explore whether nerve growth factor (NGF) plays any role in the development of peripheral neuropathy induced by anticancer treatment. We measured the circulating NGF levels in 23 cancer patients before and after chemotherapy. We evaluated whether the development of peripheral neurotoxicity was associated with changes in basal NGF concentrations in patients studied with a comprehensive neurological and neurophysiological examination. The results of these studies showed that the circulating levels of NGF, which are about 20 pg/ml in plasma of controls, decrease during chemotherapy and in some cases completely disappeared after prolonged treatment with antitumor agents. The decrease in NGF levels seems to be correlated with the severity of neurotoxicity.

These results clearly suggest that NGF might become a useful agent to prevent neuropathies induced by antineoplastic drugs and restore peripheral nerve dysfunction induced by these pharmacological compounds.

This article has been cited by other articles:

				W.-S. Wang, J.-K. Lin, T.-C. Lin, W.-S. Chen, J.-K. Jiang, H.-S. Wang, T.-J. Chiou, J.-H. Liu, C.-C. Yen, and P.-M. Chen Oral Glutamine Is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients Oncologist, March 1, 2007; 12(3): 312 - 319. [Abstract] [Full Text] [PDF]

				G. Cavaletti, G. Bogliun, L. Marzorati, A. Zincone, M. Piatti, N. Colombo, D. Franchi, M. T. La Presa, A. Lissoni, A. Buda, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy Ann. Onc., September 1, 2004; 15(9): 1439 - 1442. [Abstract] [Full Text] [PDF]

				C. Pisano, G. Pratesi, D. Laccabue, F. Zunino, P. Lo Giudice, A. Bellucci, L. Pacifici, B. Camerini, L. Vesci, M. Castorina, et al. Paclitaxel and Cisplatin-Induced Neurotoxicity: A Protective Role of Acetyl-L-Carnitine Clin. Cancer Res., November 15, 2003; 9(15): 5756 - 5767. [Abstract] [Full Text] [PDF]

				L. Vahdat, K. Papadopoulos, D. Lange, S. Leuin, E. Kaufman, D. Donovan, D. Frederick, E. Bagiella, A. Tiersten, G. Nichols, et al. Reduction of Paclitaxel-induced Peripheral Neuropathy with Glutamine Clin. Cancer Res., May 1, 2001; 7(5): 1192 - 1197. [Abstract] [Full Text]